Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439692 | 1.00 | PDE4B (0.53) | PDE4BFFAR1FFAR4PPARAMAPT | |
| SCHEMBL6438671 | 0.94 | PPARA (0.57) | PDE4BFFAR1FFAR4PPARAMAPT | |
| SCHEMBL6437129 | 0.93 | PPARA (0.58) | PDE4BFFAR1FFAR4PPARAMAPT | |
| SCHEMBL6438767 | 0.91 | HDAC1 (0.48) | PDE4BFFAR1FFAR4PPARAMAPT | |
| SCHEMBL6437472 | 0.90 | PPARA (0.55) | FFAR1FFAR4PPARAMAPTPPARG | |
| SCHEMBL8029095 | 0.89 | PDE4B (0.64) | PDE4BFFAR1FFAR4PPARAMAPT | |
| SCHEMBL13940016 | 0.88 | L3MBTL1 (0.66) | FFAR4PPARAPPARGHPGDL3MBTL1 | |
| SCHEMBL7086688 | 0.88 | PPARA (0.56) | FFAR1FFAR4PPARAPPARGALDH1A1 | |
| Hydrochloric Acid SCHEMBL8981950 | 0.87 | PDE4B (0.62) | PDE4BFFAR1FFAR4PPARAMAPT | |
| SCHEMBL6436858 | 0.85 | MEN1 (0.47) | PDE4BFFAR1FFAR4PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1506959-A2 | Derivatised molecules for mass spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | PDE4B 2749/4885FFAR1 4717/4885FFAR4 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.